Agios Pharmaceuticals, Inc. financial data

Symbol
AGIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
88 Sidney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.06K % -23.9%
Quick Ratio 30.7 % +28.5%
Debt-to-equity 13.3 % +7.11%
Return On Equity 70.2 %
Return On Assets 62 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57M shares +2.04%
Common Stock, Shares, Outstanding 57M shares +2.04%
Entity Public Float 1.56B USD +29.8%
Common Stock, Value, Issued 71K USD +1.43%
Weighted Average Number of Shares Outstanding, Basic 56.9M shares +2.04%
Weighted Average Number of Shares Outstanding, Diluted 58.4M shares +4.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 32.9M USD +36.8%
Research and Development Expense 296M USD +2.65%
General and Administrative Expense 29.1M USD +7.26%
Costs and Expenses 440M USD +7.7%
Operating Income (Loss) -407M USD -5.88%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1B USD
Income Tax Expense (Benefit) 53.1M USD
Net Income (Loss) Attributable to Parent 674M USD
Earnings Per Share, Basic 11.8 USD/shares
Earnings Per Share, Diluted 11.4 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 254M USD +294%
Cash, Cash Equivalents, and Short-term Investments 1.7B USD +94.9%
Inventory, Net 26.4M USD +53%
Assets, Current 1.07B USD +52.5%
Property, Plant and Equipment, Net 11.8M USD -29.6%
Operating Lease, Right-of-Use Asset 45.8M USD -19.8%
Other Assets, Noncurrent 4.06M USD -0.03%
Assets 1.79B USD +77.9%
Accounts Payable, Current 17.1M USD +29.2%
Employee-related Liabilities, Current 17.7M USD +26.1%
Accrued Liabilities, Current 33.3M USD +9.24%
Contract with Customer, Liability, Current 2.5M USD
Liabilities, Current 119M USD +104%
Operating Lease, Liability, Noncurrent 44.5M USD -26.8%
Other Liabilities, Noncurrent 1.16M USD 0%
Liabilities 165M USD +37.1%
Retained Earnings (Accumulated Deficit) -52.4M USD +92.8%
Stockholders' Equity Attributable to Parent 1.63B USD +83.4%
Liabilities and Equity 1.79B USD +77.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -99.9M USD -4.92%
Net Cash Provided by (Used in) Financing Activities 5.86M USD +138%
Net Cash Provided by (Used in) Investing Activities 125M USD +116%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 73.2M shares +1.58%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 254M USD +294%
Deferred Tax Assets, Valuation Allowance 380M USD +28.3%
Deferred Tax Assets, Gross 395M USD +25%
Operating Lease, Liability 60.8M USD -19.4%
Payments to Acquire Property, Plant, and Equipment 141K USD -64.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 684M USD
Lessee, Operating Lease, Liability, to be Paid 67M USD -21.7%
Property, Plant and Equipment, Gross 67.6M USD -7.45%
Operating Lease, Liability, Current 16.3M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.2M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.5M USD +4.54%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.18M USD -38.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.8M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 64.1M USD +94.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 28.6M USD +9.12%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.48M USD -83.2%
Operating Lease, Payments 18.6M USD +2.95%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 45.8M USD +7.88%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%